Marinomed Biotech Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 36

Employees

  • Share Price
  • $4.55
  • (As of Thursday Closing)

Marinomed Biotech General Information

Description

Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.

Contact Information

Formerly Known As
Marinomed Biotechnologie
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Hovengasse 25
  • Korneuburg, 2100
  • Austria
+43 02262
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Hovengasse 25
  • Korneuburg, 2100
  • Austria
+43 02262

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Marinomed Biotech Stock Performance

As of 24-Sep-2026, Marinomed Biotech’s stock price is $4.55. Its current market cap is $9.1M with 2M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.55 $4.58 $2.75 - $24.19 $9.1M 2M 8.98 $11.39

Marinomed Biotech Financials Summary

As of 31-Dec-2025, Marinomed Biotech has a trailing 12-month revenue of $8.68M.

In Thousands,
USD
TTM 31-Dec-2025 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 52,230 52,230
Revenue 8,676 8,676 5,137 9,802
EBITDA 21,409 21,409 (7,796) (4,916)
Net Income 20,325 20,325 (16,682) (6,888)
Total Assets 6,990 6,990 8,515 13,661
Total Debt 13,394 13,394 29,376 22,543
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Marinomed Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Marinomed Biotech‘s full profile, request access.

Request a free trial

Marinomed Biotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory
Biotechnology
Korneuburg, Austria
36 As of 2026

Princeton, NJ
 

Kobe, Japan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Marinomed Biotech Competitors (8)

One of Marinomed Biotech’s 8 competitors is Bristol-Myers Squibb, a Corporation company based in Princeton, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bristol-Myers Squibb Corporation Princeton, NJ
VC Cell Therapy Venture Capital-Backed Kobe, Japan
Mimetogen Pharmaceuticals Formerly VC-backed Montreal, Canada
Cipla Corporation Mumbai, India
Nicox Formerly PE-Backed Biot, France
You’re viewing 5 of 8 competitors. Get the full list »

Marinomed Biotech Patents

Marinomed Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4696300-A1 Aqueous composition comprising fluticasone Pending 14-Aug-2024
WO-2026037858-A1 Aqueous composition comprising fluticasone Pending 14-Aug-2024
WO-2025202347-A1 Composition comprising iota-carrageenan for use in the treatment of dry eyes, non-viral and non-allergic eye conditions Pending 28-Mar-2024
EP-4431082-A1 Aqueous composition comprising budesonide Inactive 13-Mar-2023
AU-2024236993-A1 Spraying device comprising aqueous budesonide composition Pending 13-Mar-2023 A61K9/0043
To view Marinomed Biotech’s complete patent history, request access »

Marinomed Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Marinomed Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Marinomed Biotech‘s full profile, request access.

Request a free trial

Marinomed Biotech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Marinomed Biotech’s complete esg history, request access »

Marinomed Biotech FAQs

  • When was Marinomed Biotech founded?

    Marinomed Biotech was founded in 2006.

  • Where is Marinomed Biotech headquartered?

    Marinomed Biotech is headquartered in Korneuburg, Austria.

  • What is the size of Marinomed Biotech?

    Marinomed Biotech has 36 total employees.

  • What industry is Marinomed Biotech in?

    Marinomed Biotech’s primary industry is Biotechnology.

  • Is Marinomed Biotech a private or public company?

    Marinomed Biotech is a Public company.

  • What is the current stock price of Marinomed Biotech?

    As of 24-Sep-2026 the stock price of Marinomed Biotech is $4.55.

  • What is the current market cap of Marinomed Biotech?

    The current market capitalization of Marinomed Biotech is $9.1M.

  • What is Marinomed Biotech’s current revenue?

    The trailing twelve month revenue for Marinomed Biotech is $8.68M.

  • Who are Marinomed Biotech’s competitors?

    Bristol-Myers Squibb, VC Cell Therapy, Mimetogen Pharmaceuticals, Cipla, and Nicox are some of the 8 competitors of Marinomed Biotech.

  • What is Marinomed Biotech’s annual earnings per share (EPS)?

    Marinomed Biotech’s EPS for 12 months was $11.39.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process